A three-microRNA panel in serum as novel biomarker for papillary thyroid carcinoma diagnosis.
10.1097/CM9.0000000000001107
- Author:
Xuan ZOU
1
;
Feng GAO
2
;
Zhi-Yan WANG
3
;
Huo ZHANG
4
;
Qing-Xie LIU
4
;
Lin JIANG
3
;
Xin ZHOU
4
;
Wei ZHU
4
Author Information
1. First Clinical College of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
2. Department of Orthopedics, First Affiliated Hospital of Nanjing Medical University, Jiangsu 210029, China.
3. Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
4. Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
- Publication Type:Journal Article
- MeSH:
Biomarkers, Tumor/genetics*;
Gene Expression Profiling;
Humans;
MicroRNAs/genetics*;
ROC Curve;
Thyroid Cancer, Papillary/genetics*;
Thyroid Neoplasms/genetics*
- From:
Chinese Medical Journal
2020;133(21):2543-2551
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Accumulating evidence has revealed that circulating microRNAs (miRNAs) can serve as non-invasive biomarkers for cancer diagnosis. This study aimed to identify differentially expressed miRNAs in serum which might become potential biomarkers for non-invasive diagnosis of papillary thyroid carcinoma (PTC).
METHODS:The experiment was carried out between 2015 and 2017. In the screening stage, the Exiqon miRNA quantitative real-time polymerase chain reaction (qPCR) panel was applied to select candidate miRNAs. In the following training, testing, and external validation stages, the serum samples of 100 patients and 96 healthy controls (HCs) were analyzed to compare the expression levels of the identified miRNAs. The areas under the receiver operating characteristic curves (AUCs) were calculated to assess the diagnostic value of the identified signature.
RESULTS:Three miRNAs (miR-25-3p, miR-296-5p, and miR-92a-3p) in serum were consistently up-regulated in PTC patients compared with HCs. A three-miRNA panel was constructed by logistic regression analysis and showed better diagnostic performance than a single miRNA for PTC detection. The AUCs of the panel were 0.727, 0.771, and 0.862 for the training, testing, and external validation stage, respectively. Meanwhile, the panel showed stable capability in differentiating PTC patients from patients with benign goiters, with an AUC as high as 0.969. For further exploration, the three identified miRNAs were analyzed in tissue samples (23 PTC vs. 23 HCs) and serum-derived exosomes samples (24 PTC vs. 24 HCs), and the altered expression in the tumor also indicated their close relationship with PTC disease.
CONCLUSION:We identify a three-miRNA panel in serum which might serve as a promising biomarker for PTC diagnosis.
